Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer

• Status: Active, not recruiting
• Trial end date: 2022-01-02

Summary

Primary Objective:

• To compare the 3-year progression free survival (PFS) in the two treatment arms.

Secondary Objectives:

• Overall survival (OS).

• Postoperative pathological stage and R0 (complete) resection rate.

• Safety: Toxicities associated with neoadjuvant chemotherapy, surgery, morbidity/mortality, toxicity of adjuvant chemotherapy.

• Phase: Phase 3

Details

• Lead Sponsor: Sanofi
• Treatments: Docetaxel; Fluorouracil; Oxaliplatin; Tegafur